Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5-fluorouracil in advanced gastric cancer refractory or intolerant to fluoropyrimidines, platinum, taxanes, and irinotecan

Kondoh, Chihiro; Kadowaki, Shigenori; Komori, Azusa; Taniguchi, Hiroya; Umemura, Takashi; Ando, Masashi; Muro, Kei

doi:10.1007/s10120-018-0825-y

Cited by 17 publications

(14 citation statements)

References 34 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tsuji et al retrospectively reported the efficacy of modified fluorouracil, leucovorin and oxaliplatin (mFOLFOX6) as fourth-or later line treatment in 14 patients who were refractory or intolerant to fluoropyrimidines, cisplatin, taxanes and irinotecan: objective response rate (ORR) of 23.1%, median progressionfree survival (PFS) of 3 months and MST of 8.9 months [16]. Similarly, in the retrospective analysis of 50 patients with similar medical history, Kondoh et al reported that mFOLFOX6 provided ORR of 21.2%, time to treatment failure (TTF) of 2.4 months, and MST of 4.2 months [17]. Thus, oxaliplatin is often used in third-or later line treatment even for patients who have history of platinum administration, and an ORR around 20% has been reported consistently (Table 1) [16][17][18][19][20][21].…”

mentioning

confidence: 98%

Consensus Molecular Subtypes of Primary Colon Tumors and Their Hepatic Metastases

et al. 2021

View full text Add to dashboard Cite

Aim: This pilot study aimed to evaluate the congruency in consensus molecular subtypes (CMS) of primary colorectal cancer and corresponding hepatic metastasis (HM). Materials & methods: RNA was extracted from both primary colorectal cancer and HM from ten patients, sequenced to establish gene-expression profiles and classified into CMS. Clinical data were collected retrospectively. Results: Of the ten patients recruited, nine had primary tumors that were classifiable: seven were CMS2, one was CMS3 and one was CMS4. Five had incongruent classification in the corresponding HM. Three out of the five patients with incongruent classification had received adjuvant chemotherapy prior to hepatic resection. Conclusion: A change in CMS type between matched primary and metastatic colorectal tumors is common and may be attributable to chemotherapy.

show abstract

mentioning

confidence: 98%

Consensus Molecular Subtypes of Primary Colon Tumors and Their Hepatic Metastases

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Tsuji et al retrospectively reported the efficacy of modified fluorouracil, leucovorin and oxaliplatin (mFOLFOX6) as fourth- or later line treatment in 14 patients who were refractory or intolerant to fluoropyrimidines, cisplatin, taxanes and irinotecan: objective response rate (ORR) of 23.1%, median progression-free survival (PFS) of 3 months and MST of 8.9 months [ 16 ]. Similarly, in the retrospective analysis of 50 patients with similar medical history, Kondoh et al reported that mFOLFOX6 provided ORR of 21.2%, time to treatment failure (TTF) of 2.4 months, and MST of 4.2 months [ 17 ]. Thus, oxaliplatin is often used in third- or later line treatment even for patients who have history of platinum administration, and an ORR around 20% has been reported consistently ( Table 1 ) [ 16–21 ].…”

Section: Background and Rationalementioning

confidence: 99%

A Phase I Study of Pevonedistat Plus Capecitabine Plus Oxaliplatin in Patients With Advanced Gastric Cancer Refractory to Platinum (NCCH-1811)

Shoji¹,

Takahari

Nagashima

et al. 2021

Future Sci. OA

View full text Add to dashboard Cite

Based on synergistic anti-tumor effects between blockades of NEDD8 activating enzyme and a platinum in preclinical studies, this Phase I study is designed to investigate the safety and tolerability of pevonedistat in combination with capecitabine plus oxaliplatin as third-line or later treatment in patients with unresectable advanced/recurrent gastric cancer who were previously treated with fluoropyrimidines and platinum (cisplatin or oxaliplatin) as the first-line treatment and paclitaxel (including nab-paclitaxel) as the second-line treatment. The aim of this trial is to determine the recommended dose of pevonedistat and to see its pharmacokinetics in combination with capecitabine plus oxaliplatin in the dose-finding part and explore its efficacy and safety in the expansion part. Trial registration number: jRCT2031190020 (jRCTs: the Japan Registry of Clinical Trials).

show abstract

“…It has a high incidence in Eastern Asia, including Ja-Oncology 2021;99:632-640 DOI: 10.1159/000517344 pan, and its occurrence is particularly common in male individuals [2]. Cytotoxic chemotherapy and targeted molecular therapy have been developed and applied for unresectable and recurrent gastric cancer and have contributed to improved prognosis [3]. However, sufficient therapeutic effects cannot be obtained with these approaches alone, and immune checkpoint inhibitors (ICIs) were thus introduced.…”

Section: Introductionmentioning

confidence: 99%

Lymphocyte-to-Monocyte Ratio Is a Predictive Biomarker of Response to Treatment with Nivolumab for Gastric Cancer

et al. 2021

View full text Add to dashboard Cite

Introduction: Patients with unresectable or recurrent gastric cancer who have an objective response (OR) to nivolumab monotherapy are expected to have a good long-term prognosis. However, the OR rate for nivolumab treatment is low at 11%, and there is a need for biomarkers to predict the treatment response. This study aimed to analyze the significance of systemic inflammation-related variables and clinicopathologic characteristics as predictive markers of response to nivolumab monotherapy in patients with advanced gastric cancer. Methods: In this retrospective cohort study, we enrolled 71 consecutive patients who received nivolumab monotherapy for unresectable or recurrent gastric cancer. Receiver operating characteristic curve analysis was performed to determine the cutoff values of systemic inflammation-related variables, predictors of treatment response, and other prognostic factors related to nivolumab therapy. We focused on systemic inflammation-related variables measured before nivolumab induction and 2 weeks after its first administration and performed multivariate analysis to assess whether they could be used as prognostic factors. Results: Multivariate analysis revealed that a lymphocyte-to-monocyte ratio (LMR) of ≤3.28 after 2 weeks of initial nivolumab treatment (2wLMR) is a statistically significant predictor of treatment response (p = 0.012). The progression-free survival (PFS) rate of patients with liver metastasis was significantly worse than that of the other patients (1-year PFS: 0.0 vs. 24.4%, respectively; p = 0.005). The overall survival (OS) of patients with a low 2wLMR was significantly longer than that in patients with a high 2wLMR (1-year OS: 37.4 vs. 18.9%, respectively; p = 0.022). Conclusions: Thus, the 2wLMR could be a useful biomarker to predict response to nivolumab treatment and the prognosis of unresectable and recurrent gastric cancer.

show abstract

Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5-fluorouracil in advanced gastric cancer refractory or intolerant to fluoropyrimidines, platinum, taxanes, and irinotecan

Abstract: Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5-fluorouracil has a potential activity and is tolerable for heavily treated AGC with appropriate dose modification and patient selection.

Cited by 17 publications

References 34 publications

Consensus Molecular Subtypes of Primary Colon Tumors and Their Hepatic Metastases

Consensus Molecular Subtypes of Primary Colon Tumors and Their Hepatic Metastases

A Phase I Study of Pevonedistat Plus Capecitabine Plus Oxaliplatin in Patients With Advanced Gastric Cancer Refractory to Platinum (NCCH-1811)

Lymphocyte-to-Monocyte Ratio Is a Predictive Biomarker of Response to Treatment with Nivolumab for Gastric Cancer

Contact Info

Product

Resources

About